Meiragtx Holdings vs Novavax
Novavax is the larger business, with $1.12bn of revenue in fiscal 2025 against $81.4m for Meiragtx Holdings (13.8 times as much). Meiragtx Holdings grew faster (144.6% against 64.7%). Novavax kept more of each dollar of sales as profit: a net margin of 39.2% against -140.3%.
| Latest fiscal year | Meiragtx HoldingsMGTX, 2025 | NovavaxNVAX, 2025 |
|---|---|---|
| Revenue | $81.4m | $1.12bn |
| Revenue growth | 144.6% | 64.7% |
| Net income | −$114m | $440m |
| Operating margin | -130.2% | 40.3% |
| Net margin | -140.3% | 39.2% |
| Return on equity | — | — |
| Free cash flow | −$50.2m | −$250m |
| Cash | $65.9m | $241m |
| Total debt | $74.3m | $244m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 403 | 749 |
| Market value | $887m | $1.58bn |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | 19 (Weak) |
| Insider trades, 12 months | 0 buys, 10 sales | 0 buys, 0 sales |